Nootropic Peptides: A Research Overview of Selank, Semax, Cerebrolysin, and Pinealon

Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.

Introduction

Within the broader peptide research literature, the term “nootropic peptides” describes a structurally diverse research class with one common feature: each member has been investigated in preclinical models of cognition, neuroprotection, or central nervous system signaling. Nootropic peptides research encompasses molecules ranging from short synthetic heptapeptides like Selank and Semax to complex neurotrophic preparations like Cerebrolysin and tripeptide bioregulators such as Pinealon. Several of these compounds have a long Eastern European pharmacological history, with the majority of primary literature originating from Russian research groups during the 1990s and 2000s.

This article surveys the nootropic peptides research class — outlining the biology, mechanisms, and preclinical research applications of Selank, Semax, Cerebrolysin, N-acetylated peptide variants, and Pinealon. Each compound has been studied for distinct aspects of CNS signaling, but the class as a whole occupies an active and growing area of peptide neuroscience research.

Peptide Class Overview

Nootropic peptides do not share a single mechanism or receptor target. Some — like Selank — are tuftsin-derived heptapeptides with effects on monoaminergic systems. Others — like Semax — are ACTH(4-10) fragment analogs with BDNF-modulating activity. Cerebrolysin is a complex preparation of low-molecular-weight peptides and amino acids derived from porcine brain tissue. Pinealon and related compounds developed in the Khavinson cytogen/peptide bioregulator school are short tripeptides hypothesized to interact with chromatin and modulate gene expression. P21, derived from CNTF, has been developed as a brain-penetrant neurogenic peptide. Cortexin, like Cerebrolysin, is a multi-component cortical peptide preparation with a long Eastern European research history.

What unites them is their experimental application: all are studied in CNS-focused preclinical research, often involving behavioral models, neurotrophic factor measurement, neuroinflammation assays, and electrophysiology endpoints. Several are administered intranasally in research protocols to bypass first-pass metabolism and exploit nose-to-brain transport pathways. Others are administered parenterally (subcutaneously, intraperitoneally, or intravenously) depending on the specific preparation and experimental design.

A defining feature of the nootropic peptide research class is the predominance of Eastern European and Russian primary literature. Compounds such as Selank, Semax, Cerebrolysin, Pinealon, and Cortexin all originated in Russian or other Eastern European research institutes, with foundational publications in the 1980s and 1990s. English-language replication and mechanistic refinement of this research base has continued through the 2000s and 2010s, with major contributions from neuroscience groups in Western Europe and North America. Researchers approaching this class for the first time should familiarize themselves with both the Russian-origin primary literature (often translated in journals such as Bulletin of Experimental Biology and Medicine) and the more recent English-language replication and extension studies.

Shared Mechanisms and Research Context

Across the nootropic peptides class, several mechanistic themes recur. Modulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB has been documented in multiple studies. Effects on monoaminergic neurotransmission — dopaminergic, serotonergic, and noradrenergic — appear in the literature on Selank, Semax, and Cerebrolysin. Neuroprotection in models of ischemia, oxidative stress, and excitotoxicity is a recurrent endpoint. The class is particularly active in research areas including memory consolidation models, anxiety-related behavior, age-related cognitive decline studies, and post-injury recovery investigations.

A distinguishing feature of the nootropic peptide research class is the emphasis on intranasal administration as a route of CNS delivery. The olfactory and trigeminal nerve pathways provide direct anatomical access from the nasal mucosa to the brain, bypassing first-pass hepatic metabolism and partially circumventing the blood-brain barrier. For short, water-soluble peptides such as Selank and Semax, intranasal administration can produce measurable CNS exposure within minutes and is the most-used route in preclinical neuroscience research with these compounds. The choice of intranasal versus parenteral routes shapes both the experimental design and the interpretation of resulting data.

A second shared feature is the gene-expression endpoint. Multiple members of the nootropic peptide research class produce broad transcriptomic changes detectable by qPCR, microarray, or RNA-seq within hours of administration. These gene-expression panels typically encompass neurotrophic factors (BDNF, NGF, GDNF), inflammatory cytokines, synaptic plasticity-related genes (Arc, Egr1, c-fos), and apoptosis-related genes (Bcl-2, Bax). The pattern and magnitude of gene-expression change varies by compound and region, providing a mechanistic readout that complements behavioral assessments.

Key Research Areas

1. Selank — Tuftsin-Derived Anxiolytic Research Peptide

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a synthetically stabilized analog of tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg) derived from the heavy chain of human immunoglobulin G. The addition of a C-terminal Pro-Gly-Pro tripeptide confers resistance to enzymatic degradation. Volkova et al. (2016) and others have characterized Selank’s effects on GABAergic, serotonergic, and dopaminergic systems in rodent models of anxiety-related behavior [1]. Subsequent studies demonstrated that Selank modulates BDNF content in the hippocampus and prefrontal cortex of rats and protects against ethanol-induced memory impairment [2]. Kasian et al. (2017) characterized Selank’s effects on monoaminergic neurotransmission, reporting altered turnover of serotonin and norepinephrine in selected rat brain regions following intranasal administration [9]. Research-grade Selank is widely used in studies of anxiety circuitry, stress resistance, and immunomodulation.

2. Semax — ACTH(4-10) Analog with BDNF Modulation

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment of adrenocorticotropic hormone. Like Selank, the C-terminal Pro-Gly-Pro tripeptide stabilizes the molecule against enzymatic degradation. Semax was developed at the same Russian institute and has been studied for over three decades. Shadrina et al. (2010) and Dolotov et al. (2006) demonstrated that intranasal Semax produces rapid and sustained upregulation of BDNF and TrkB expression in the rat hippocampus and basal forebrain [3, 4]. Eremin et al. (2005) characterized Semax’s effects on dopaminergic and serotonergic brain systems in rodents [5]. The peptide has been investigated in models of cerebral ischemia, optic nerve injury, and cognitive performance. Medvedeva et al. (2014) further reported that Semax administration in rats following focal ischemia altered the expression of genes involved in inflammatory and apoptotic signaling pathways, supporting a multi-target neuroprotective profile [10]. Research-grade Semax is supplied as a lyophilized powder for preclinical neuroscience applications.

3. Cerebrolysin — Neurotrophic Peptide Preparation

Cerebrolysin is a complex preparation produced by enzymatic breakdown of purified porcine brain proteins. It consists of low-molecular-weight peptides (≤10 kDa) and free amino acids that mimic the actions of endogenous neurotrophic factors. Unlike single-sequence peptides, Cerebrolysin is a multi-component preparation, which introduces unique analytical considerations for research characterization. Masliah and Díez-Tejedor (2012) reviewed its pharmacology, describing Cerebrolysin as a peptide preparation with neurotrophic and neuroprotective activity in models of acute and chronic CNS disorders [6]. Zhang et al. (2010) demonstrated that Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcomes in a rat model of stroke [7]. Rockenstein et al. (2007) reported that the preparation reduced amyloid pathology and improved behavioral performance in an APP-transgenic mouse model of Alzheimer’s disease, suggesting effects on amyloid processing pathways [11]. The preparation has been studied in cerebral ischemia models, Alzheimer’s disease models, and traumatic brain injury research.

4. N-Acetylated Peptide Variants

N-acetylation — the covalent addition of an acetyl group to the N-terminal amino acid — is a well-established peptide engineering strategy that confers resistance to aminopeptidase cleavage and modulates blood-brain barrier permeability. N-acetyl Selank (NAS) and N-acetyl Semax (NAS-Semax) are studied analogs that exhibit extended plasma stability compared with their parent compounds. Research on N-acetylated nootropic peptide variants typically focuses on pharmacokinetic characterization, comparative receptor activity, and behavioral endpoints in standard rodent models. Inozemtsev et al. (2008) reported that N-acetylation of Semax extends measurable behavioral effects following peripheral administration in rats, consistent with reduced first-pass enzymatic clearance. The choice between an acetylated and non-acetylated analog in a research design depends primarily on the desired duration of action — short-pulse pharmacological probes typically use the unmodified peptide, while studies requiring extended receptor engagement may use the acetylated form.

5. Pinealon — Khavinson Tripeptide Bioregulator

Pinealon (Glu-Asp-Arg) is a synthetic tripeptide developed within the Khavinson “peptide bioregulator” research tradition, in which short peptides derived from organ-specific extracts are hypothesized to act as epigenetic regulators of gene expression. Pinealon has been investigated in cellular models for cytoprotective and neuroprotective effects, with research suggesting modulation of stress-response gene expression and protection of neuronal cells under hypoxic and oxidative stress conditions. Khavinson et al. and subsequent investigators have published on Pinealon in studies of cognitive aging models and neuronal cell viability assays [8]. Subsequent fluorescence-microscopy work has reported penetration of FITC-labeled tripeptides into nuclei of cultured neurons, providing a structural basis for the proposed direct gene-regulatory mechanism — though the precise binding partners remain an open question in the literature.

6. P21 (Cerebrolysin-Derived Tetrapeptide)

P21 is an experimental small peptide (Ac-DGGLAG-amide) derived from the bioactive sequence of ciliary neurotrophic factor (CNTF) and developed as a brain-penetrant analog with neurogenic and synaptogenic activity in preclinical neuroscience models. Bolognin et al. (2014) reported that P21 enhanced neurogenesis and synaptogenesis in cultured neurons and in a 3xTg mouse model of Alzheimer’s-like pathology, with concomitant cognitive improvements in maze-based assessments [12]. P21 has been studied as a research probe for the relationship between trophic factor signaling, adult hippocampal neurogenesis, and learning behavior.

7. Cortexin and Related Cortical Peptide Preparations

Cortexin is a complex peptide preparation of low-molecular-weight peptides (typically <10 kDa) extracted from bovine or porcine cerebral cortex. Like Cerebrolysin, Cortexin is supplied as a multi-component preparation rather than a single-sequence peptide and has been studied in cerebral ischemia models, cognitive aging research, and neurodevelopment paradigms. The polypeptide composition reflects the original cortical proteome and includes both signaling peptides and structural fragments. Cortexin research has primarily been conducted in Eastern European laboratories, with characterization studies emphasizing electrophysiological effects on hippocampal long-term potentiation models and protection against glutamate excitotoxicity in cultured neurons.

Cross-Compound Mechanistic Comparison

The seven principal nootropic peptide research compounds outlined above engage distinct but partially overlapping biological pathways. The following comparison highlights the mechanistic distinctions that researchers should consider when selecting compounds:

The table makes clear that the nootropic peptide research class is not unified by a single receptor or pathway, but by an experimental domain — investigation of CNS biology with peptide tools. The mechanistic diversity within the class is in fact one of its strengths, allowing researchers to select tools that map onto specific questions about neurotransmitter systems, growth factor signaling, neuroprotective mechanisms, or epigenetic regulation of CNS gene expression.

Experimental Design Considerations Specific to Nootropic Peptide Research

Several design considerations are particularly important when working with nootropic research peptides. First, behavioral assays should be selected to match the proposed mechanism. For peptides hypothesized to act on anxiety-related circuits (Selank, NAS), the elevated plus maze, light-dark box, and Vogel conflict test are standard. For peptides hypothesized to act on cognitive consolidation (Semax, P21, Cerebrolysin), the Morris water maze, Barnes maze, and novel object recognition test are appropriate. For peptides hypothesized to act on stress-coping behavior, the forced swim test and tail suspension test are common — though these tests have well-documented limitations in their construct validity.

Second, the timing of behavioral assessment relative to peptide administration substantially affects outcomes. Acute effects (within hours of administration) reflect direct pharmacological actions; subchronic effects (over days to weeks of repeated administration) may reflect adaptive changes such as BDNF expression modulation, neurogenesis, or synaptic remodeling. Many studies of Selank and Semax document differing effect profiles at acute vs. subchronic timepoints, supporting the importance of pre-specified time points in study design.

Third, sex differences and circadian effects can confound results. Behavioral assays in rodents show sex differences in baseline anxiety-related and cognitive measures, and nootropic peptide effects can interact with these baseline differences. Many published studies have used only male animals, but the NIH and other research funders increasingly require inclusion of both sexes. Circadian timing also matters — corticosterone levels, baseline arousal, and neurotransmitter turnover all vary across the light-dark cycle, and behavioral assays performed at different circadian phases produce different results.

Fourth, for intranasal administration protocols, the delivery technique substantially affects bioavailability. Volumes greater than approximately 10 μL per nostril in mice or 50 μL per nostril in rats can cause runoff into the oropharynx and reduce nose-to-brain delivery. Position of the animal during administration (head tilt, anesthesia status) also affects mucosal distribution and uptake. Published protocols document these methodological details, and researchers should report administration technique alongside dose and timing.

Selection Criteria for Researchers

Choosing among nootropic research peptides depends on the experimental question. Several practical criteria help guide selection:

• Mechanism focus: For studies of HPA axis interactions and stress-response circuitry, Selank and Semax (both Pro-Gly-Pro–stabilized peptides with documented monoaminergic activity) are the most-studied tools. For neurotrophic-pathway research focused on BDNF/TrkB signaling, Semax has the largest English-language preclinical literature base. For broader neuroprotection studies, Cerebrolysin and P21 provide multi-component or single-peptide trophic-factor mimetic options.
• Route of administration: Selank and Semax are most commonly administered intranasally in preclinical research, exploiting nose-to-brain transport pathways that bypass first-pass metabolism. Cerebrolysin is typically administered parenterally in research protocols. Pinealon and other Khavinson tripeptides have been studied across both routes.
• Literature maturity: Selank and Semax have the deepest and most cross-laboratory-replicated preclinical literature in this class. Cerebrolysin has an extensive English-language clinical literature outside the United States and a substantial preclinical record. Pinealon, P21, and other newer compounds have smaller but growing primary literature bases.
• Combination potential: Selank + Semax co-administration has been studied in some preclinical paradigms for additive monoaminergic and BDNF effects, and represents one of the most accessible nootropic peptide stacks in the published literature.

For all selections, researchers should ensure that the peptide is supplied at ≥98% HPLC purity with mass spectrometry confirmation and that the Certificate of Analysis documents counterion identity, since trifluoroacetate (TFA) versus acetate counterions can influence experimental outcomes in some assays.

Research Considerations for Laboratory Use

Nootropic peptides are typically supplied as lyophilized powders at ≥98% HPLC purity. Storage at −20°C is standard for long-term archiving; reconstituted solutions are commonly maintained at 2–8°C and used within 2–4 weeks. Bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution solvent for most members of this class. For peptides containing methionine (such as Semax), researchers should minimize exposure to air to limit methionine oxidation during long-term storage of reconstituted material. Each batch should be accompanied by a Certificate of Analysis documenting sequence identity, purity, and counterion content. For intranasal delivery research protocols, careful attention to formulation pH and excipient compatibility is important.

For behavioral research designs, the timing of administration relative to the behavioral assay matters substantially. Short-acting peptides such as Selank and Semax typically produce peak CNS effects within 30–60 minutes of intranasal administration, with effects waning over 2–4 hours. Acetylated variants (NAS, NAS-Semax) extend this window. The Cerebrolysin preparation, owing to its multi-component composition and slower distribution, is typically administered hours before assay timepoints. Researchers should document the precise timing of administration in any published study.

Cross-laboratory replication of nootropic peptide effects has been variable, particularly for compounds with primary literature concentrated in Russian-language journals. When designing studies, researchers should review both English-language and translated primary literature, with attention to differences in administration route, dose, and outcome measures across reports. Pre-registration of study designs, including pre-specified primary endpoints, contributes to the methodological maturity of this research area.

Conclusion

The nootropic peptides research class is a heterogeneous but increasingly active area of preclinical neuroscience. From the synthetic heptapeptides Selank and Semax — both stabilized derivatives of biologically meaningful parent sequences — to the complex Cerebrolysin preparation, the short tripeptide bioregulators like Pinealon, the neurotrophic-derived P21, and the cortical peptide preparation Cortexin, these compounds provide researchers with tools for investigating BDNF signaling, monoaminergic modulation, neuroinflammation, neuroprotection, and cognitive-behavioral endpoints in animal models.

Because much of the foundational literature originated in Russian-language journals, English-language replication is still developing for several class members. The next phase of nootropic peptide research is likely to focus on receptor identification, mechanistic refinement, and broader cross-laboratory replication. Combination studies — for example, pairing Selank with Semax for additive monoaminergic and BDNF effects, or studying Pinealon alongside short-acting tripeptide bioregulators in aging-relevant paradigms — will likely contribute additional mechanistic insight as the research area matures.

For laboratory researchers selecting compounds in this class, the selection criteria outlined earlier provide a practical framework: match the peptide to the experimental question, attend to route-of-administration considerations, ensure analytical quality through CoA review, and design studies with attention to timing and replication. The combination of these practical considerations with mechanistically targeted hypotheses is what advances this research class beyond exploratory description into rigorous preclinical neuroscience.

References

1. Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26973524.

1. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neurosci Med. 2013;4(4):223–252. Selank tuftsin analog research summary. PMID: 31625062.

1. Shadrina M, Kolomin T, Agapova T, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under intranasal Semax administration. Brain Res. 2010. PMID: 16996037.

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82–86. PMID: 16635254.

1. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493–1500. PMID: 16362768.

1. Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc). 2012;48 Suppl A:3–24. PMID: 22514792.

1. Zhang C, Chopp M, Cui Y, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res. 2010;88(15):3275–3281. PMID: 20857512.

1. Khavinson VK, Tarnovskaya SI, Linkova NS, et al. Short cell-penetrating peptides EDR and AEDG: pharmacological effects and mechanisms of action. Adv Gerontol. 2014. Pinealon (EDR) bioregulator characterization. PMID: 32019204.

1. Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. Peptide Selank enhances the effect of paroxetine in reducing depressive-like behavior in rats. Behav Brain Res. 2017;329:111-117. PMID: 28442363.

1. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. PMID: 24661821.

1. Rockenstein E, Adame A, Mante M, et al. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer’s disease with the neurotrophic compound Cerebrolysin. J Neural Transm Suppl. 2007;72:283-296. PMID: 17982904.

1. Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014;35(9):2134-2146. PMID: 24813636.

Explore our lab-tested Selank and Semax → /product/selank-10mg/ | /product/semax/